# Eastman Chemical Co: financial statements, quarterly

EMN · NYSE · CIK 915389 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/emn.md) · [Financials](/companies/emn/financials.md) · [Filings](/companies/emn/filings.md) · [Insiders](/companies/emn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/emn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,207 d](/filings/0000915389-26-000013.md) | [2,310](/filings/0000915389-25-000105.md) | [2,363](/filings/0000915389-25-000155.md) | [2,464](/filings/0000915389-25-000183.md) | [2,245 d](/filings/0000915389-26-000013.md) | [2,290](/filings/0000915389-26-000099.md) | [2,287](/filings/0000915389-26-000141.md) | [2,202](/filings/0000915389-26-000172.md) | [1,973 d](/filings/0000915389-26-000013.md) | [2,177](/filings/0000915389-26-000099.md) | [2,513](/filings/0000915389-26-000141.md) | [2,385](/filings/0000915389-26-000172.md) |
| Cost of revenue | $m | [1,743 d](/filings/0000915389-26-000013.md) | [1,778](/filings/0000915389-25-000105.md) | [1,764](/filings/0000915389-25-000155.md) | [1,859](/filings/0000915389-25-000183.md) | [1,691 d](/filings/0000915389-26-000013.md) | [1,723](/filings/0000915389-26-000099.md) | [1,781](/filings/0000915389-26-000141.md) | [1,769](/filings/0000915389-26-000172.md) | [1,635 d](/filings/0000915389-26-000013.md) | [1,746](/filings/0000915389-26-000099.md) | [1,953](/filings/0000915389-26-000141.md) | [1,853](/filings/0000915389-26-000172.md) |
| Gross profit | $m | [464 d](/filings/0000915389-26-000013.md) | [532](/filings/0000915389-25-000105.md) | [599](/filings/0000915389-25-000155.md) | [605](/filings/0000915389-25-000183.md) | [554 d](/filings/0000915389-26-000013.md) | [567](/filings/0000915389-26-000099.md) | [506](/filings/0000915389-26-000141.md) | [433](/filings/0000915389-26-000172.md) | [338 d](/filings/0000915389-26-000013.md) | [431](/filings/0000915389-26-000099.md) | [560](/filings/0000915389-26-000141.md) | [532](/filings/0000915389-26-000172.md) |
| Research and development | $m | [57.0 d](/filings/0000915389-26-000013.md) | [59.0](/filings/0000915389-25-000105.md) | [60.0](/filings/0000915389-25-000155.md) | [65.0](/filings/0000915389-25-000183.md) | [66.0 d](/filings/0000915389-26-000013.md) | [67.0](/filings/0000915389-26-000099.md) | [67.0](/filings/0000915389-26-000141.md) | [63.0](/filings/0000915389-26-000172.md) | [58.0 d](/filings/0000915389-26-000013.md) | [60.0](/filings/0000915389-26-000099.md) | [65.0](/filings/0000915389-26-000141.md) | [63.0](/filings/0000915389-26-000172.md) |
| Selling, general and administrative | $m | [191 d](/filings/0000915389-26-000013.md) | [191](/filings/0000915389-25-000105.md) | [180](/filings/0000915389-25-000155.md) | [183](/filings/0000915389-25-000183.md) | [182 d](/filings/0000915389-26-000013.md) | [182](/filings/0000915389-26-000099.md) | [157](/filings/0000915389-26-000141.md) | [160](/filings/0000915389-26-000172.md) | [159 d](/filings/0000915389-26-000013.md) | [178](/filings/0000915389-26-000099.md) | [185](/filings/0000915389-26-000141.md) | [171](/filings/0000915389-26-000172.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [114 d](/filings/0000915389-26-000013.md) | [49.0](/filings/0000915389-25-000105.md) | [56.0](/filings/0000915389-25-000155.md) | [99.0](/filings/0000915389-25-000183.md) | [(34.0) d](/filings/0000915389-26-000013.md) | [70.0](/filings/0000915389-26-000099.md) | [29.0](/filings/0000915389-26-000141.md) | [65.0](/filings/0000915389-26-000172.md) | [(71.0) d](/filings/0000915389-26-000013.md) | [29.0](/filings/0000915389-26-000099.md) | [72.0](/filings/0000915389-26-000141.md) | [(4.0)](/filings/0000915389-26-000172.md) |
| Net income | $m | [310 d](/filings/0000915389-26-000013.md) | [165](/filings/0000915389-25-000105.md) | [230](/filings/0000915389-25-000155.md) | [180](/filings/0000915389-25-000183.md) | [330 d](/filings/0000915389-26-000013.md) | [182](/filings/0000915389-26-000099.md) | [140](/filings/0000915389-26-000141.md) | [69.0](/filings/0000915389-26-000172.md) | [83.0 d](/filings/0000915389-26-000013.md) | [107](/filings/0000915389-26-000099.md) | [183](/filings/0000915389-26-000141.md) | [252](/filings/0000915389-26-000172.md) |
| Diluted EPS | $ per share | not reported | [1.39](/filings/0000915389-25-000105.md) | [1.94](/filings/0000915389-25-000155.md) | [1.53](/filings/0000915389-25-000183.md) | not reported | [1.57](/filings/0000915389-26-000099.md) | [1.20](/filings/0000915389-26-000141.md) | [0.60](/filings/0000915389-26-000172.md) | not reported | [0.93](/filings/0000915389-26-000099.md) | [1.59](/filings/0000915389-26-000141.md) | [2.19](/filings/0000915389-26-000172.md) |
| Basic EPS | $ per share | not reported | [1.40](/filings/0000915389-25-000105.md) | [1.96](/filings/0000915389-25-000155.md) | [1.55](/filings/0000915389-25-000183.md) | not reported | [1.58](/filings/0000915389-26-000099.md) | [1.22](/filings/0000915389-26-000141.md) | [0.60](/filings/0000915389-26-000172.md) | not reported | [0.93](/filings/0000915389-26-000099.md) | [1.60](/filings/0000915389-26-000141.md) | [2.21](/filings/0000915389-26-000172.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.5](/filings/0000915389-25-000012.md) | not reported | not reported | not reported | [0.8](/filings/0000915389-26-000013.md) | not reported | not reported | not reported | [0.6](/filings/0000915389-26-000013.md) | not reported | not reported | not reported |
| Current assets | $bn | [3.5](/filings/0000915389-25-000012.md) | [3.6](/filings/0000915389-24-000133.md) | [3.8](/filings/0000915389-24-000192.md) | [3.9](/filings/0000915389-24-000227.md) | [4.1](/filings/0000915389-26-000013.md) | [3.9](/filings/0000915389-25-000105.md) | [4.0](/filings/0000915389-25-000155.md) | [3.8](/filings/0000915389-25-000183.md) | [3.6](/filings/0000915389-26-000172.md) | [4.1](/filings/0000915389-26-000099.md) | [4.3](/filings/0000915389-26-000141.md) | [4.4](/filings/0000915389-26-000172.md) |
| Total assets | $bn | [14.6](/filings/0000915389-25-000012.md) | [14.7](/filings/0000915389-24-000133.md) | [14.9](/filings/0000915389-24-000192.md) | [15.1](/filings/0000915389-24-000227.md) | [15.2](/filings/0000915389-26-000013.md) | [15.0](/filings/0000915389-25-000105.md) | [15.2](/filings/0000915389-25-000155.md) | [15.0](/filings/0000915389-25-000183.md) | [14.9](/filings/0000915389-26-000172.md) | [15.2](/filings/0000915389-26-000099.md) | [15.4](/filings/0000915389-26-000141.md) | [15.5](/filings/0000915389-26-000172.md) |
| Current liabilities | $bn | [2.6](/filings/0000915389-25-000012.md) | [2.6](/filings/0000915389-24-000133.md) | [2.7](/filings/0000915389-24-000192.md) | [2.6](/filings/0000915389-24-000227.md) | [2.7](/filings/0000915389-26-000013.md) | [2.3](/filings/0000915389-25-000105.md) | [2.4](/filings/0000915389-25-000155.md) | [2.2](/filings/0000915389-25-000183.md) | [2.7](/filings/0000915389-26-000172.md) | [2.8](/filings/0000915389-26-000099.md) | [2.8](/filings/0000915389-26-000141.md) | [2.8](/filings/0000915389-26-000172.md) |
| Total liabilities | $bn | [9.1](/filings/0000915389-25-000012.md) | [9.1](/filings/0000915389-24-000133.md) | [9.2](/filings/0000915389-24-000192.md) | [9.3](/filings/0000915389-24-000227.md) | [9.4](/filings/0000915389-26-000013.md) | [9.0](/filings/0000915389-25-000105.md) | [9.3](/filings/0000915389-25-000155.md) | [9.1](/filings/0000915389-25-000183.md) | [8.8](/filings/0000915389-26-000172.md) | [9.1](/filings/0000915389-26-000099.md) | [9.2](/filings/0000915389-26-000141.md) | [9.1](/filings/0000915389-26-000172.md) |
| Long-term debt | $bn | [4.3](/filings/0000915389-25-000012.md) | [4.3](/filings/0000915389-24-000133.md) | [4.3](/filings/0000915389-24-000192.md) | [4.6](/filings/0000915389-24-000227.md) | [4.6](/filings/0000915389-26-000013.md) | [4.7](/filings/0000915389-25-000105.md) | [4.8](/filings/0000915389-25-000155.md) | [4.8](/filings/0000915389-25-000183.md) | [4.2](/filings/0000915389-26-000172.md) | [4.5](/filings/0000915389-26-000099.md) | [4.5](/filings/0000915389-26-000141.md) | [4.5](/filings/0000915389-26-000172.md) |
| Short-term borrowings | $bn | [0.5](/filings/0000915389-25-000012.md) | [0.7](/filings/0000915389-24-000133.md) | [0.7](/filings/0000915389-24-000192.md) | [0.4](/filings/0000915389-24-000227.md) | [0.5](/filings/0000915389-26-000013.md) | [0.3](/filings/0000915389-25-000105.md) | [0.3](/filings/0000915389-25-000155.md) | [0.3](/filings/0000915389-25-000183.md) | [0.6](/filings/0000915389-26-000172.md) | [0.8](/filings/0000915389-26-000099.md) | [0.8](/filings/0000915389-26-000141.md) | [0.8](/filings/0000915389-26-000172.md) |
| Shareholders' equity | $bn | [5.5](/filings/0000915389-25-000012.md) | [5.5](/filings/0000915389-24-000133.md) | [5.6](/filings/0000915389-24-000192.md) | [5.7](/filings/0000915389-24-000227.md) | [5.8](/filings/0000915389-26-000013.md) | [5.9](/filings/0000915389-25-000105.md) | [5.8](/filings/0000915389-25-000155.md) | [5.8](/filings/0000915389-25-000183.md) | [6.0](/filings/0000915389-26-000172.md) | [6.0](/filings/0000915389-26-000099.md) | [6.1](/filings/0000915389-26-000141.md) | [6.3](/filings/0000915389-26-000172.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [452 d](/filings/0000915389-26-000013.md) | [(16.0)](/filings/0000915389-25-000105.md) | [367 d](/filings/0000915389-25-000155.md) | [396 d](/filings/0000915389-25-000183.md) | [540 d](/filings/0000915389-26-000013.md) | [(167)](/filings/0000915389-26-000099.md) | [233 d](/filings/0000915389-26-000141.md) | [402 d](/filings/0000915389-26-000172.md) | [502 d](/filings/0000915389-26-000013.md) | [(137)](/filings/0000915389-26-000099.md) | [224 d](/filings/0000915389-26-000141.md) | [290 d](/filings/0000915389-26-000172.md) |
| Capital expenditure | $m | [179 d](/filings/0000915389-26-000013.md) | [185](/filings/0000915389-25-000105.md) | [115 d](/filings/0000915389-25-000155.md) | [120 d](/filings/0000915389-25-000183.md) | [179 d](/filings/0000915389-26-000013.md) | [147](/filings/0000915389-26-000099.md) | [150 d](/filings/0000915389-26-000141.md) | [137 d](/filings/0000915389-26-000172.md) | [112 d](/filings/0000915389-26-000013.md) | [103](/filings/0000915389-26-000099.md) | [100 d](/filings/0000915389-26-000141.md) | [95.0 d](/filings/0000915389-26-000172.md) |
| Dividends paid | $m | [94.0 d](/filings/0000915389-26-000013.md) | [95.0](/filings/0000915389-25-000105.md) | [95.0 d](/filings/0000915389-25-000155.md) | [95.0 d](/filings/0000915389-25-000183.md) | [94.0 d](/filings/0000915389-26-000013.md) | [96.0](/filings/0000915389-26-000099.md) | [95.0 d](/filings/0000915389-26-000141.md) | [96.0 d](/filings/0000915389-26-000172.md) | [94.0 d](/filings/0000915389-26-000013.md) | [96.0](/filings/0000915389-26-000099.md) | [96.0 d](/filings/0000915389-26-000141.md) | [96.0 d](/filings/0000915389-26-000172.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [120](/filings/0000915389-24-000133.md) | [120](/filings/0000915389-24-000192.md) | [119](/filings/0000915389-24-000227.md) | [118](/filings/0000915389-25-000105.md) | [119](/filings/0000915389-25-000155.md) | [118](/filings/0000915389-25-000183.md) | [117](/filings/0000915389-26-000099.md) | [116](/filings/0000915389-26-000141.md) | [115](/filings/0000915389-26-000172.md) | [115](/filings/0000915389-26-000099.md) | [115](/filings/0000915389-26-000141.md) | [115](/filings/0000915389-26-000172.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 114,380,456 at 2026-09-30, from the cover of the [10-Q filed 2026-10-30](/filings/0000915389-26-000172.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 12:26 ET. No prices; not investment advice.